ENDRA Life Sciences Inc. has announced new results from a recently completed feasibility study of its TAEUS® Liver device, designed for the early detection and monitoring of steatotic liver disease (SLD). The study, which included 40 subjects with a BMI range of 21 to 47, demonstrated that the TAEUS thermo-acoustic fat fraction (TAFF) measurement closely matches the performance of MRI-PDFF, the current gold standard, at key liver fat fraction (LFF) thresholds of 12-17% and 20-22%. These thresholds are significant for clinical therapy decisions and clinical trial enrollment. The device achieved an average positive predictive value (PPV) of 100% and accuracy of 95% in the 12-17% LFF range, and a PPV of 90% and accuracy of 94% in the 20-22% range. ENDRA is conducting a second feasibility study in London, Ontario, Canada, expected to be completed in the coming months, and plans to engage with the FDA in 2026 regarding a pivotal study to support a De Novo submission.